Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles

Abstract

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.

Keywords: 11q deletion; anti-GD2 therapy; immune checkpoint inhibition; microRNAs.